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- Protein phosphatase 2A  
98%
400
protein kinase  [28, 34]
PPP PPM Asp phosphatase
40 protein phosphatase
[17]  Protein phosphatase 1 PP1 PP5 type 2A protein phosphatase







C PP2Ac A PP2A 
A B
ABC B B B55/PR55 B B56/PR61 B
PR72/PR130 B PR93/PR110 20
 [125] A
3
A  Protein phosphatase 2A PP2A
















hTERT telomerase catalytic subunit H-RAS
SV40-ER
 [57] SV40-ER
protein SV40-LT small-t protein SV40-ST


















 [113] P179R AC B55 B56





 [135, 138] PME-1
PP2A PP2Ac
PP2A  [149] PME-1
ERK1/2
 [110, 140] SET
PP2A ERK1/2 Akt
cMyc E2F1













































- - PPZ T
T T PPZ
T HUT78 T
CCRF-CEM SKW3 Jurkat TALL1 PPZ
A T
PPZ T Ema
UL-1 PPZ B PPZ
T
PPZ
PBMC PPZ PBMC Ema UL-1 PPZ





A T HUT78 T
CCRF-CEM Jurkat TALL1 SKW3 PPZ
72 CCK8 PPZ 100%
N = 6
B T  Ema UL-1 PPZ
72 CCK8 PPZ
100% N = 6
C PBMC Ema UL-1 PPZ 72
CCK8 PPZ



































- - PPZ T
PP2A
 [49, 139] PPZ T
HUT78
UL-1 PPZ cleaved active
caspase 3 A-D PPZ cleaved caspase 3
Annexin V-FITC Apoptosis Kit Bio Vison FACS
PPZ HUT78 UL-1





A-D HUT78 A B PPZ 12 24 UL-1 C D PPZ
12 cleaved active caspase 3 western blotting
A C  PPZ 100% B D N = 3 * Ð < 
0.05 PPZ
E F HUT78 E UL-1 F PPZ 12 FACS

































PPZ 0 12 hr













0 12 24 hr
14
- -  PPZ T Akt
HUT78 UL-1 PPZ
Akt A-F PPZ 15-30 Akt
Thr308 Ser473
Akt Thr308 PDK1  [4] Akt Ser473 mTORC2
 [123] PDK1 Ser241  [25]
mTORC2 Akt Ser473 NDRG1
mTORC2  [51] HUT78
UL-1 PPZ 15 PDK1 NDRG1
PPZ PDK1 NDRG1
G-L











































































































0 60 12015 30 min
p-Akt Ser473
16
 PPZ T Akt
A-F HUT78 A-C PPZ UL-1 D-F PPZ
15-120 Akt Thr308 Ser473 western 
blotting A D 0 min 100%
Akt Thr308 B E Akt Ser473 C F N = 3 * Ð < 
0.05 0 min
G-L HUT78 G-I PPZ UL-1 J-L PPZ 15
PDK1 NDRG1 western blotting
G J 0 min 100% PDK1 H K
NDRG1 I L N = 3
17
- - PPZ T ERK1/2
Akt ERK1/2 PP2A
HUT78 UL-1 PPZ
ERK1/2 PPZ A-D PPZ
ERK1/2
HUT78 UL-1
ERK1/2 MEK1/2 MEK1/2 Ser217 Ser221




PPZ MEK1/2 B-Raf C-Raf [93]
I-N
HUT78 PPZ B-Raf C-Raf
UL-1 B-Raf














































































































 PPZ T ERK1/2
A-D HUT78 A B PPZ UL-1 C D PPZ
15-120 ERK1/2 western blotting
A C 0 min 100% ERK1/2 B D
N = 3 * Ð < 0.05 0 min
E-H HUT78 E F PPZ UL-1 G H PPZ 15
MEK1/2 western blotting
E G 0 min 100% MEK1/2 F H N = 
3 * Ð < 0.05 0 min
I-N HUT78 I-K PPZ UL-1 L-N PPZ 15
B-Raf C-Raf western blotting
I L 0 min 100% B-Raf J M
C-Raf K N N = 3 * Ð < 0.05 0 min
20
- - PPZ PP2A Akt ERK1/2
PPZ Akt Ser473 ERK1/2 Thr202/Tyr204 PP2A
A B PP2A okadaic acid OA
[47] PP2A HUT78 UL-1 PPZ




ERK1/2 PP1 PP2B  [64, 157]
PPZ ERK1/2 PP1 PP2B PP1
tautomycin TAU [37] PP2B cyclosporin A CsA [79] 
HUT78 UL-1 PPZ ERK1/2
C D TAU CsA PPZ ERK1/2
ERK1/2 PP2C DUSP1/6
 [119, 159] PP2C sanguinarine SA [1] DUSP1/6
BCI [97] HUT78 UL-1 PPZ 15-30
ERK1/2 E F SA BCI PPZ
ERK1/2
Na3VO4 PPZ ERK1/2





















































































PPZ PP2A Akt ERK1/2
A B HUT78 UL-1 ocadaic acid OA 100 nM
PPZ HUT78 UL-1 15-30 Akt Ser473
ERK1/2 western blotting N = 3
C D HUT78 UL-1 tautomycin TAU cyclosporin A CsA 10 
PPZ HUT78 UL-1 15-30
ERK1/2 western blotting N = 3
E HUT78 sanguinarine PPZ
15-30 ERK1/2 western blotting N = 
2
F HUT78 BCI 1 PPZ 15-30
ERK1/2 western blotting N = 2
G H HUT78 Na3VO4 1 PPZ
15-30 ERK1/2 western blotting
G Na3VO4 PPZ 0 min 100% H N = 3
*/# Ð<0.05
24
- - Akt T
PPZ T Akt
ERK1/2 Akt
Akt inhibitor VIII ERK1/2 FR180204 MEK1/2 U0126
HUT78 UL-1 Akt inhibitor VIII





HUT78 UL-1 U0126 Akt ERK1/2
ERK1/2 CREB G






A-F HUT78 A C E UL-1 B D F Akt inhibitor VIII 0-30 
A B FR180204 C D U0126 E F 72
CCK8 100%
N = 4 * Ð < 0.05
G H HUT78 G UL-1 H U0126 24 Akt Ser473

































































































































 [41, 82, 152] Caspase 3
poly ADP-ribose polymerase PARP
 [46] PPZ
cleaved active caspase 3 PPZ
PP2A
















PPZ Akt Thr308 Ser473
29
PPZ Akt Akt Thr308 PDK1
Ser473 mTORC2  [4, 123] Akt Thr308
TSC1/2  [68] Akt Ser473
FOXO1
 [68] PPZ PDK1 mTORC2
Akt PP2A PPZ
Akt PP2A B56g












 [107] D1 D5
D2 D3 D4  [11] T
 [15, 158] D1 D5 protein kinase A PKA Ras
ERK1/2  [102] D2 D3 D4 PKA
ERK1/2 [14] D2
PP2A Akt PP2A Akt
 [112]
Raji Namalwa Daudi Jijoye
dopamine  [15]
C-Raf B-Raf MEK1/2 ERK1/2
PPZ ERK1/2
PPZ D2
[107] D2 PPZ Akt
PPZ Akt
PPZ




 [8, 13, 87] HUT78 UL-1
ERK1/2 PPZ
ERK1/2
MEK1/2 ERK1/2 PP1 PP2A PP2B PP2C DUSP1/6










 [59, 86] PPZ
32
PP2A
small molecular activator of PP2A SMAP
 [58, 73, 91, 113, 122, 134] SMAP












- -  PP2A SET
SET I2PP2A TAF-1
ÍÛÌóÝßÒ ÍÛÌóÒËÐîïì  [85]
SET
ERK1/2 Akt



















 [72] SET PP2A
SET PP2A
PP2A
- -  SET PP2A
Apolipoprotein E ApoE
178 277
 [31]  ApoE SET





 [103] FTY720 
 [32, 98, 105, 115]
T OP449 FTY720


















- -  SET
POS
HM-POS SET SET
PP2A  [100] POS HM-POS
SET PP2Ac SET PP2Ac
A B
POS HM-POS SET shRNA



































































































A B POS HM-POS SET PP2Ac
A POS SET PP2Ac 100
B N = 3
C D POS HM-POS shNT shSET
SET C shNT
100 D N = 3 * Ð < 0.05 shNT
E POS HM-POS shNT shSET
Day1-4 CCK8 shNT
Day1 100 N = 6 * Ð < 0.05 shNT
F G POS HM-POS shNT shSET
F shNT
100 G
N = 6 * Ð < 0.05 shNT
41
- -  SET
SET PP2A ERK1/2 mTORC1 Akt
 [45, 72, 131]
SET
POS SET ERK1/2
HM-POS SET ERK1/2 mTORC1
p70S6K A-H




POS A C E G HM-POS B D F H shNT shSET
ERK1/2 (A B) MEK1/2 (C D)  p70S6K (E F) Akt (G H)
shNT 100 N = 3













































































































































































































- -  SET
SET PP2A E2F1 cMyc






HM-POS SET ERK1/2 mTORC E2F1
44
SET
POS A C E HM-POS B D F shNT shSET
E2F1 A B C D cMyc E F
shNT

































A POS HM-POS FR180204 72
CCK8 FR180204
100% N = 6 * Ð < 0.05 FR180204
B C POS HM-POS FR180204 10
B FR180204










































A POS HM-POS FTY720 72
CCK8 FTY720
100% N = 6 * Ð < 0.05 FTY720
B POS HM-POS FTY720 cisplatin 72
CCK8






















































































 [43, 72, 76] SET







































 [147] B56 B56g3 B56g
PP2A
 [27, 117, 141]
PP2A/B56 cMyc Akt
p53
[75] SMAP PP2A A
B56 A
 [122] PP2A/B56
- -  SET PP2A





 [43] SET ERK1/2
p70S6K E2F1
E2F1  [43]
ERK1/2 PP2A/B56g1 p70S6K PP2A/B56g
PP2A/B56g
 [19, 56, 76] SET PP2A/B56












- -  SETa PP2A/B56
SET PP2A FLAG
B 293T SET
B A B SETa B55 PR72


































































A B 293T FLAG B FLAG M2
B SET
A FLAG
B56g3 SET 100 B N = 3 Empty








- -  SETa B56a B56g3
- - -  SETa B56a B56g3
SETa B56 B56a
B56g3 SETa B56
HEAT A B B56a B56g3 N
C SETa WT
C-H B56a B56g3 N C
SETa N
PP2Ac C PP2Ac
B56a C SETa PP2Ac
PP2Ac SETa




















































A B B56a B56g3 SETa PP2Ac
WT
C-H 293T FLAG B56a C-E B56g3
F-H FLAG M2 B56a B56g3
SET C F
FLAG WT SETa D G PP2Ac E H 100
N = 3
62
- - -  B56a B56g3 SETa
SET CD ED AD
A B56a
B56g3 B B56a





A SETa B56a B56g3 CD
ED AD CD ED
CE  ED AD EA WT
B C 293T FLAG B56a B B56g3 C GFP


























































- -  SETa B56a B56g3
B56g3 SETa SET
SET CD
 [95] SET B56g3
SETa SETa DD  [95] A
SETa DD SETa DD SETa WT
B SETa DD
C SETa DD SETa
B56g3 SETa DD B56g3
D E
SETa B56g3
B56a SETa SETa B56a
SETa B56a
B F





















WT WT WT DD DD



































































































SETa 2 B56a B56g3
A SETa DD
B 293T FLAG SETa WT GFP SETa WT
SETa DD FLAG M2 SETa WT
SETa WT SETa DD
Empty N = 3




D 293T FLAG B56g3 GFP SETa WT
SETa DD FLAG M2 B
SETa WT SETa DD
Empty N = 3




F 293T FLAG B B55a B55d B56a B56g2
PR72 GFP SETa WT SETa DD FLAG 
M2 B SETa WT SETa DD
Empty  N 
= 3
G 293T DD SmBiT-B56a 24
100
N = 4








































100 N = 4
C-E A549-nSETa/cSETa-C6 C D KN-93 0.5-10 
E
DMSO 100 N = 4-6 D * Ð <= 0.001
E * Ð <= 0.005
F A549 LSm-BiT A549-LSm-G1 5 
KN-93
DMSO 100 N = 
4
73






A B SETa B56a B56g3
74
KN-93 SETa-B56a SETa-B56g3
A B A549 SmBiT-B56a SmBiT-B56g3
A A549-nSETa/nB56a B:A549-nSETa/nB56g3
KN-93 DMSO

























 [61, 124, 132] 
KN-93




A-D KN-92 SETa KN-93
W-7 KN-62
SETa
KN-93 Fyn Hck Lck MLCK
TrkA  [108] Fyn Hck







A-E A549-nSETa/cSETa-C6 A KN-92 B W-7 C KN-62 D
E CHR6494
DMSO 100 N = 4 B * Ð = 
0.023 C * Ð = 0.002
77



















DMSO 100 N = 4 * Ð < 0.01
B A549-nSETa/cSETa-C6
KN-93 -
100 N = 4 * Ð < 0.01
C A549-nSETa/cSETa-C6
KN-92
DMSO 100 N = 4
D A549-LSm-G1
KN-93 DMSO
100 N = 4 * Ð < 0.05
E A549-nSETa/cSETa-C6
DMSO 100 N = 4
F A549-LSm-G1
DMSO 100 N = 4
80
-
- -  SETa PP2A
SET
ÍÛÌóÝßÒ ÍÛÌóÒËÐîïì  [85]
PP2Ac B
PP2A PP2A
I2PP2A SET  [6, 84] PP2Ac
95~112 133~146 SETb SETb 1~18 151~172
165~182 PP2Ac  [133] SET PP2Ac
SET PP2A
È»²±°«­ ´¿»ª·­ SET B55d B56g
PR48  [62] SET






 [118, 151] B56a  [48] B56g2
81
 [67] B56g3  [92] B56a B56g3
SETa B56
SETa B56 PP2Ac
B56g3 C PP2Ac 
PP2Ac SETa
B56a B56g3 SETa
- -  SET PP2A
SET SET SETb
importin
 [151] PKC CK2
 [103, 154] CD
SETa N 1
37 SETb 1 24
SETa N




 [103] PP2A SET
FTY720 SETb CD Gln29 Lys77
SETb PP2Ac  [36]
SET PP2A
FTY720 SETa






















- -  SETa B56
B56a B56g3 SETa AD B56a






B56g3 SETa CD CE
84




- - KN-93 SETa
SETa
KN-93 SETa
 [108, 144] W-7
KN-62






















PP2A PP2A PAD PP2A
PID PAD PP2A SMAP PPZ
SET-PP2A FTY720 OP449 PID LB100

















 [36] FTY720 S1P
 [20] FTY720
SPHK2 S1P  [1]
S1P
FTY720
 [24] SET FTY720
  [103] SPHK2 FTY720 OSU-2S S1P


















66cl4  [153] B55a
Thr41
 [81, 156] PR130











SET  [16, 43, 
49, 65, 66, 72] SET
BCR-ABL JAK2 SET
 [100] Myc SP1
RUNX1 GATA2 SET SET mRNA
 [109] Myc RUNX1
 [89, 106]















proteolysis targeting chimeric molecules PROTACs
 [121]

















T HUT78 T CCRF-CEM
SKW3 Jurkat TALL1 T UL-1
Ema PBMC POS
HM-POS AA Thermo Scientific 10% fetal 
FBS SIGMA RPMI1640
A549 293T Takara Bio 1% AA 10% FBS
Eagles medium DMEM SIGMA 37°C 5% CO2
MCO-5AC SANYO SCA-80D ASTEC
HBS 25 mM HEPES 150 








InFusion HD Cloning Kit Takara Bio
95
C GFP DD
DD PCR InFusion HD 
Cloning Kit pLVGFPc N GST
N 8×His pLVSIN 
PCR InFusion HD 
Cloning Kit pGEX4T1 pHEX1 LgBiT
SmBiT N C
WT




pLVmC ClaI/MluI T4 DNA ligase Takara Bio
shRNA
Non-target shRNA shNT   5-CAACAAGATGAGAGCACCA-3 
SET target shRNA shSET   5-GGATGAAGGTGAAGAAGAT-3 
- -
XL10GOLD Stratagene HST08 Takara Bio 10 µL
0.5 µL 30 Major Science
42°C 45 50 µL LB 
96
Broth 50 µL super optimal broth with catabolite repression SOC Medium
37°C BioShaker BR-22FP Taitec LB agar
100 µg/mL ampicillin 37°C
LB Broth 100 µg/mL ampicillin 37°C
200 rpm 4,000 rpm 10
 2420 KUBOTA Plasmid Mini 
Kit I Omega
- -
12 293T 2×105 cell/well 200 µL
Opti-MEM  1.0 µg PolyethylenimineMAX PEI Polysciences




packaging plasmid psPAX2 VSVG coat protein 
plasmid pMD2.G 2.5 µL PEI Opti-MEM






BL21 DE3 Codon Plus RP Agilent Technologies 50 uL
30
LB Broth 100 µg/mL ampicillin 35 µg/mL chloramphenicol
37°C 250 rpm 200 mL LB 
Broth 100 µg/mL ampicillin 35 µg/mL chloramphenicol 1 L
37°C 200 rpm IPTG isopropyl 
0.2 mM
37°C 200 rpm 3,000 rpm 15 4°C
recombinant buffer A 20 mM Tris HCl pH 7.5 150 mM NaCl
recombinant buffer B 20 mM Tris HCl pH 7.5 150 mM NaCl 0.1 
mM EGTA 5 mM benzamidine 1 mM PMSF 1 mM DTT 0.1% Tween 20
20 mM Tris HCl pH 7.5 150 mM NaCl 0.1 mM EGTA 5 mM 
benzamidine 1 mM PMSF 20 mM imidazole 0.1% Tween 20 10 ml lysozyme
4°C
12,000 rpm 10 KUBOTA




PD-10 GE Healthcare recombinant storage buffer 20 mM Tris HCl 
pH 7.5 150 mM NaCl 0.01% Tween 20
coomassie brilliant blue CBB
CBB CBB 0.1% coomassie brilliant blue
50% methanol 10% acetic acid CBB 7.5% acetic acid 5% methanol
-  Western blotting
- -
1,500 rpm
Lysate buffer 50 mM Tris-HCl pH 8.0 5 mM EDTA 5 mM EGTA 1 mM Na3VO4
20 mM sodium pyrophosphate 1% Triton X-100 1 tablet/50 mL Roche Complete 
protease inhibitor HBS
lysate buffer
°C 15,000 rpm 15
- -  Western blotting 
 DC protein assay kit Bio-Rad
Lowry 10-40 µg SDS
99
8-15% Bio-Rad PVDF Bio-Rad
Wako PVDF
0.5% 3% TBS-T 25 mM Tris-HCl pH 7.4 150 mM NaCl
0.05% Tween 20 30-60 °C
1 ECL Pro western blotting Detection 
Reagent PerkinElmer LAS3000mini FUJIFILM
ImageJ National Institutes of Health
p97/VCP
- pull down assay 
- -  FLAG M2
HBS CHAPS 
lysate buffer 40 mM HEPES pH 7.4 2 mM EDTA 10 mM disodium 
glycerophosphatate 0.3% CHAPS 10 mM sodium pyrophosphate 2 tablet/50 mL 
PhosSTOP 1 tablet/50 mL Roche Complete protease inhibitor
°C 15,000 rpm 15
CHAPS wash buffer 40 mM 
HEPES pH 7.4 2 mM EDTA 10 mM disodium glycerophosphatate 0.3% CHAPS 10 
mM sodium pyrophosphate FLAG M2 Affinity Gel SIGMA
°C 30 SDS 
100
sample buffer 50 mM Tris-HCl pH 6.8 0.4% SDS 2% 
Glycerol FLAG peptide SIGMA western blotting
- -  GST pull down assay 
100 pmol GST-tag 100 pmol 10 pmol
glutathione sepharose recombinant buffer A °C 30
SDS sample buffer western 
blotting
-
Cell Counting Kit-8 Dojindo











293T 1.0×104 96 Perkin Elmer 6005181
24 LgBiT- SmBiT-
100 ng PEI Opti-MEM 30
24 Nano-Glo Live Cell 
Substrate Nano-Glo LCS Dilution Buffer 5 95
25 µL 10 37°C % CO2
37°C ARVO X PerkinElmer
GloMAX Promega 10













































SmBiT c56 n56 c56 n56
c56 c56 n56 n56 LgBiT
SmBiT c56 n56 c56 n56
c56 c56 n56 n56
103
- -  NanoBiT A549
PCR
pLVnB2puro pLVnB2neo - -
A549
NanoBiT A549
- -  NanoBiT A549
96
A549 2.0×104 24
20 CellTox Lysis Solution
Promega 10 µL Nano-Glo Live Cell 
Substrate CellTox Green Nano-Glo LCS Dilution Buffer 5 1 94
25 µL 10 37°C % CO2







- -  In vitro NanoBiT
A549 1.0×105
CHAPS IP Buffer 15,000 rpm 15
in vitro NanoBiT in vitro 
NanoBiT 96 Thermo Scientific 611F96WT
4°C 0.625 11.74





HUT78 PPZ 24 UL-1 PPZ 12
105
1,500 rpm
Annexin V-FITC Apoptosis Kit Bio Vision Annexin V




t-test One way ANOVA Fishers Least 
Significant Difference LSD test P 5%
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p-Akt Ser473 Cell Signaling 4060 
p-Akt Thr307 Cell Signaling 13038 
Akt Cell Signaling 2920 
p-B-Raf Ser445 Cell Signaling 5284 
p-C-Raf Ser338 Cell Signaling 9427 
cleaved caspase 3 Asp175 Cell Signaling 9664 
caspase 3 Gene Tex GTX11-543 
p-cMyc Ser62 Bio Academia 71-161 
cMyc Santa Cruz sc-764 
p-CREB Ser133 Cell Signaling 9198 
p-E2F1 Ser364 MBL D246-3 
E2F1 Santa Cruz sc-193 
p-ERK1/2 Thr202/Tyr204 Cell Signaling 9101 
ERK1/2 Cell Signaling 9107 
FLAG Sigma F7425 
GFP Santa Cruz sc-9996 
p-GSK3b Ser9 Cell Signaling D85E12 
GSK3b Santa Cruz sc-9166 
GST ABGent 9AT106 
His Gene Tex GTX115044 
p-MEK1/2 Ser217/Ser221 Cell Signaling 9154 
MEK1/2 Cell Signaling 4694 
p-NDRG1 Thr346 Cell Signaling 5482 
p-PDK1 Ser241 Cell Signaling 3438 
PDK1 Cell Signaling 3062 
p-p70S6K Thr389 Cell Signaling 9234 
107
p70S6K Santa Cruz sc-230 
PP2Ac Millipore 07-324 
SET Santa Cruz sc-5655 
SET Santa Cruz sc-133138 




Cycrosporine A Wako 
Sanguinarine EXTRASYNTHESE 
BCI Merck Millipore 
FR180204 SIGMA 
FTY720 Cayman Chemical 
Cisplatin Wako 
Xanthohumol Cayman Chemical 
KN-93 Wako 
W-7 Cayman Chemical 
KN-62 Cayman Chemical 
CHR6494 Tocris Bioscience 
KN-92  R&D SYSTEMS 
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